Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the transaction, the insider directly owned 20,422 shares of the company’s stock, valued at $593,054.88. The trade was a 26.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.58, for a total value of $54,891.10.

Stoke Therapeutics Stock Up 2.4%

Shares of STOK opened at $32.71 on Friday. The company has a market cap of $2.11 billion, a PE ratio of -9.79 and a beta of 1.20. The business has a fifty day moving average of $30.45 and a 200 day moving average of $32.05. Stoke Therapeutics, Inc. has a 52-week low of $12.86 and a 52-week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Stoke Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $44.00 target price on the stock. Canaccord Genuity Group decreased their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a report on Monday, May 11th. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently made changes to their positions in STOK. BlackRock Inc. purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter worth $192,307,000. Janus Henderson Group PLC grew its stake in Stoke Therapeutics by 333.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after purchasing an additional 1,116,452 shares during the last quarter. State Street Corp raised its holdings in Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after purchasing an additional 1,072,176 shares in the last quarter. Corient Private Wealth LLC bought a new position in Stoke Therapeutics in the second quarter worth about $7,489,000. Finally, Troluce Capital Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at about $21,255,000.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target on STOK to $40 while maintaining an “outperform” rating, signaling confidence in the company’s pipeline and potential upside. Wedbush raises Stoke Therapeutics price target
• Positive Sentiment: Chardan Capital reiterated a “buy” rating on Stoke Therapeutics, adding to the favorable analyst sentiment surrounding the biotechnology company. Chardan Capital buy rating
• Neutral Sentiment: Canaccord Genuity remained constructive on the shares but issued a more cautious price outlook, reflecting a mixed analyst view despite continued confidence in Stoke’s long-term prospects. Canaccord Genuity forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright cut its projected EPS for fiscal 2026 to a loss of $3.35 from $3.09, fiscal 2027 to a loss of $2.55 from $2.05, and fiscal 2028 to a loss of $1.78 from $0.67. It also reduced quarterly estimates to losses of $0.81 per share, indicating expectations for higher or more prolonged expenses. HC Wainwright earnings forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright’s broader outlook remains bearish for later years, with its FY2029 EPS forecast reportedly reduced to $1.55 from $1.63. The revisions highlight execution and commercialization risks for Stoke’s pipeline. HC Wainwright FY2029 forecast
• Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct holdings by 26%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still weigh modestly on sentiment. SEC insider sale filing

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.